

Supplementary Table 1 Different treatments for oesophageal gastrointestinal stromal tumours

Parameter	Our research	Lian <i>et al.</i> (2024)	Zhou <i>et al.</i> (2020)	Mohammadi <i>et al.</i> (2021)
Surgical selection	Endoscopic resection	Endoscopic resection	Endoscopic resection	Segmental resection without reconstruction
Number of patients	32	23	16	6
Age	57.78 ± 7.39	61 (43-72)	/	64.3 ± 9.0
Sex				
Male	18 (56.3%)	11 (47.8%)	7	
Localization				
Upper	2 (6.3%)	3 (13%)	4	0 (0%)
Middle	10 (31.3%)	12 (52.2%)	5	5 (8.3%)
Lower	20 (62.5%)	8 (34.8%)	7	1 (16.7%)
Tumour size (cm)	1.50 (0.80-2.75)	≤2.0 cm: 9 (39.1%) 2-4cm: 14 (60.9%)	< 1cm: 8 1-2cm: 7 > 2cm: 1	4.5 (0.8-6.7)
Mitotic rate				
Mean (per 50HPF, ± SD)	3.34 ± 5.04	≤5: 22 (95.7%) > 5: 1 (4.3%)	< 5: 14 5-10: 1 > 10: 1	< 5: 3 (50.0%) > 5: 2 (33.3%) Unknown: 1 (16.7%)
NIH risk category				
High	6 (18.8%)	1 (4.3%)		/

Intermediate	2 (6.3%)	0 (0)	1	/
Low	6 (18.8%)	13 (56.5%)	3	/
Very Low	18 (56.3%)	9 (39.1%)	12	/
Operation time, mean (± SD), min	52.63 ± 43.29	± 53.6 (25-111)		/
Hospital stay duration, day	4.22 ± 2.21	4.5 (3-8)	< 3 day: 1 3-5 day: 9 > 5 day: 6	/
Surgical resection				
En bloc resection	31 (96.8%)	23 (100%)		5 (83.3%)
Complication, n (%)	8 (25.0%)	0 (0%)	4	2 (33.3%)
Follow-up time				
Mean (mean ± SD)	64.69 ± 33.13	± /	27.81 ± 21.07	/
Survival data				
Recurrence	3	0 (0%)	0	2 (33.3%)
Survival rates (%)				
5-year OS	100%	/	100%	/